Anti-Tumor Necrosis Factor Alpha Treatment and Tuberculin Skin Test

Year 2015, , 430 - 438, 30.09.2015

Emine Duygu Bozkırlı , Müge Tufan Lale Özışık Nazan Şen Ahmet Yücel

https://doi.org/10.17826/cutf.82507

Abstract

Purpose: The use of anti-tumor necrosis factor alpha (anti-TNF) drugs has been a milestone in the treatment of rheumatic diseases. Despite their strong efficacy, there are some factors restricting the use of anti-TNF agents. We must be careful especially for the granulomatous diseases which can be seen endemic in our country such as tuberculosis and leishmaniasis. In our country according to the RAED 2005 Consensus Meeting Reports, patients candidate for anti-TNF treatment are evaluated for both active and inactive tuberculosis before treatment and prophylaxis with isoniazid (INH) has been performed where indicated. Material and Methods: Tuberculin skin tests (TST) of 43 patients followed up in the Rheumatology Clinic and receiving anti-TNF therapy were repeated under treatment. Patients’ pretreatment first TST results, drugs they used, INH prophylaxis state, smoking status and the duration of anti-TNF treatment were evaluated. Results: 14 patients (32.6%) were women, while 29 (67.4%) were men. The mean of first TST values were 11.72±90.3 mm (0-30) and the mean of second TST values were 12.06±12.4 mm (0-45). 48.8% of the patients were smoking and 74.4% of the patients had received INH prophylaxis for 9 months. The mean total duration of anti-TNF drug use was found as 22.67±19.11 (5-68) months. No statistically significant difference (p=0.888) was observed between the first pretreatment and second under treatment TST results of the patients. Discussion: Tuberculosis remains to be a serious public health problem for both our country and the whole world. For this reason in our country, a detailed assessment is performed for all patients before anti-TNF treatment. In our study patients who are planned to start anti-TNF therapy were assessed with their first TST values and INH prophylaxis were given to 32 patients (74.4%) before treatment. No statistically significant difference was observed between pre and posttreatment TST values when control TST were performed with the earliest after five months of treatment. These findings may suggest that there is no evident increase in the risk of tuberculosis for patients receiving anti-TNF treatment with appropriate INH prophylaxis.

Keywords

TNF, tuberculin skin test, tuberculosis, ankylosing spondylitis, rheumatoid arthritis, spondyloarthropathy

Anti-Tümör Nekroz Faktör Alfa Tedavisi ve Tüberkülin Cilt Testi

Abstract

Giriş: Anti tümör nekroz faktör-α (anti-TNF) ilaçların kullanıma girmesi romatolojik hastalıkların tedavisi için bir dönüm noktası olmuştur. Güçlü etkilerine rağmen anti-TNF ajanların kullanımını kısıtlayan bazı faktörler vardır. Tüberküloz ve leişmanyaz gibi ülkemizde endemik olarak da gözlenebilen granülomatöz hastalıklar açısından özellikle dikkatli olunmalıdır. Ülkemizde RAED 2005 yılı Uzlaşı Toplantısı Raporu dikkate alınarak hastaların tedavi öncesi hem aktif hem de inaktif tüberküloz açısından değerlendirmeleri yapılmakta ve gereken hastalara izoniazid (INH) ile profilaksi yapılmaktadır. Materyal ve Metod: Romatoloji kliniğinde takip edilen ve anti-TNF tedavi almakta olan 43 hastanın tedavi altında tüberkülin cilt testi(TCT) testi tekrarlandı. Tedavi öncesi ilk TCT değeri, kullandıkları ilaçlar, INH profilaksi durumu, sigara kullanımı, anti-TNF ilaç kullanım süreleri değerlendirildi. Bulgular: Hastaların 14(%32.6)’ü kadın, 29(%67.4)’ü erkekti. İlk TCT ortalaması 11.72±90,3 mm (0-30) ve 2. TCT ortalaması 12.06±12.4 mm (0-45) idi. %48.8 hasta sigara kullanıyordu ve %74.4 hasta 9 ay INH profilaksisi kullanmıştı. Hastaların toplam ilaç kullanım süreleri ortalama 22.67±19.11 ay (5-68) olarak saptandı. Hastaların anti-TNF tedavi öncesindeki ilk TCT düzeyleri ile tedavi altında bakılan 2. TCT değerleri arasında istatistiksel olarak anlamlı fark (p=0.888) saptanmadı. Tartışma: Tüberküloz gerek dünyada gerekse ülkemizde hâlâ ciddi bir halk sağlığı sorunu olmaya devam etmektedir. Bu nedenle ülkemizde tedavi öncesi hastalar ayrıntılı olarak incelenmektedir. Çalışmamızda anti-TNF tedavi başlanması planlanan hastalar İlk TCT değerlerine göre değerlendirilmiş ve tedavi öncesi 32(%74.4) hastaya izoniazid profilaksisi başlanmıştır. Tedavi altındaki hastalara en erken 5 ay sonra olmak üzere kontrol TCT yapıldığında istatistiksel olarak anlamlı fark saptanmadı. Bu bulgularla anti-TNF tedavi alan hastalarda uygun izoniazid profilaksisi ile tüberküloz riskinde belirgin artış olmadığı öngörülebilir

Keywords

TNF, tüberkülin cilt testi, tüberküloz, ankilozan spondilit, romatoid artrit, spondiloartropati

References

• Scott, D.L. and G.H. Kingsley, Tumor necrosis factor inhibitors for rheumatoid arthritis. N Engl J Med 2006;355:704-12.
• Pham T, Fautrel B, Dernis E, Goupille P, Guillemin F, Le Loët X et al. Recommendations of the French Society for Rheumatology regarding TNFalpha antagonist therapy in patients with ankylosing spondylitis or psoriatic arthritis: 2007 update. Joint Bone Spine 2007;74:638-46.
• Öcal S, Demir N, Ataman Ş, Demir AU, Kayacan O.
• TNF-a Antagonist Tedavi Planlanan Hastalarda Latent Tüberküloz İnfeksiyon Tanı ve Tedavi Yaklaşımı. Solunum Hastalıkları. 2013;24:47–52.
• Hamilton CD. Infectious complications of treatment with biologic agents. Curr Opin Rheumatol 2004; 16:393-8.
• Hyrich KL, Silman AJ, Watson KD, Symmons DP. Anti-tumour necrosis factor alpha therapy in rheumatoid arthritis: an update on safety. Ann Rheum Dis. 2004;63:1538-43.
• Gardam MA, Keystone EC, Menzies R, Manners S, Skamene E, Long R, Vinh DC. Anti-tumour necrosis factor agents and risk: mechanism of action and clinical managament. Lancet Infect Dis. 2003;3:148- 55.
• Maeda T, Banno SMS, Naniwa T, Hayami Y, Watanabe M, Sato S, Ueda R. Comparison of Quantiferon-TB Gold and the tuberculin skin test for detecting previous tuberculosis infection evaluated by chest CT findings in Japanese rheumatoid arthritis patients. J Infect Chemother. 2011;17:842-8.
• Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries. 2014; WHO.
• Ozsahin SL, akkurt I, Ozdemir L, Doğan OT, Atalan
• A, Kocoglu F. Are official reports sufficient? Official registration rates of patients with tuberculosis in Sivas, Middle Anatolia. Public Health. 2006;120:434- 40.
• Şakar A, Göktalay T, Dağyıldızı L, Yıldırım CA, Yorgancıoğlu A. Screening of tuberculosis in school children in Manisa city. Toraks. 2002;4:38-42.
• Tanrıkulu Ç, Abakay A, Abakay Ö, Alp A. Tuberculosis screening results made at primary schools in Cizre. Tüberk Toraks. 2006;54:336-40.
• Arriola-delos Reyes CM, Sanches L, Ong-Lim AL,Gonzales LM. A paired comparison of tuberculin skin manifestations of tuberculosis using 2 tu and 5 tu tuberculins. PIDSP Journal. 2011;12:56-66. clinical
• Kenney RT, Rangdaeng S, Scollard DM. Skin blister immunocytology. A new method to quantify cellular kinetics in vivo. J Immunol Methods. 1987;97:101-10.
• Picker LJ, Treer JR, Ferguson-Darnell B, Collins PA, Bergstresser PR, Terstappen LW. Control of lymphocyte recirculation in man. II. Differential regulation of the cutaneous lymphocyte-associated antigen, a tissue-selective homing receptor for skin- homing T cells. J Immunol 1993;150:1122–36.
• Picker LJ, Martin RJ, Trumble A, Newman LS, Collins PA, Bergstresser PR, et al. Differential expression of lymphocyte homing receptors by human memory/effector T cells inpulmonary versus cutaneous immune effector sites. Eur J Immunol. 1994;24:1269–77.
• Keser GDH, Akkoç N, İnanç M, Özkara Ş, Öngen G, Gül A, Uçan ES, Ertenli İ, Yazıcı H, Doğanavşargil E, Romatizma araştırma ve eğitim derneği uzlaşı toplantı raporu. 2005, Romatizma araştırma ve eğitim derneği uzlaşı toplantı raporu. İzmir.
• Doran Mf, Crowson CS, Pond GR, O’Fallon WM, Gabriel SE. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based 2002;46:2287-93. Arthritis Rheum.
• Au K, Reed G, Curtis JR, Kremer JM, Greenberg JD, Strand V, Fursr DE. High disease activity is associated with an increased risk of infection in patients with rheumatoid arthritis. Ann Rheum Dis. 2011;70:785-91.
• Solovic I, Sester M, Gomez-Reino JJ, Rieder HL, Ehlers S, Milburn HJ, Kampmann B et al. The risk of tuberculosis related to tumour necrosis factor Antagonist statement. Eur Respir J. 2010;36:1185-206. TBNET consensus
• Dixon WG, Watson K, Lunt M, Hyrich KL, Silman AJ, Symmons DP. British Society for Rheumatology Biologics Register. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society Register.Arthritis Rheum. 2006;54:2368-76. Biologics
• Jung YJ, Lyu J, Yoo B, Lee CK, Kim YG, Yang SK, Byeon JS et al. ombined use of a TST and the T SPOT(R).TB assay for latent tuberculosis infection diagnosis before anti-TNF alpha treatment. Int J Tuberc Lung Dis. 2012;16):1300-6.
• Huebner RE, Schein MF, Bass JB Jr. The tuberculin skin test. Clin Infect Dis. 1993;17:968-75.
• American Thoracic Society. Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR Recomm Rep. 2000;49(RR-6):1-51.
• Mazurek GH, Jereb j, Vernon A, LoBue P, Goldberg S, Castro K. Updated guidelines for using Interferon Gamma Release Assays to detect Mycobacterium tuberculosis infection United States, 2010. MMWR Recomm Rep 2010;59(RR-5):1-25
• Tsiouris SJ, Coetzee D, Toro PL, Austin J, Stein Z, El-Sadr W. Sensitivity analysis and potential uses of a novel gamma interferon release assay for diagnosis of tuberculosis. J Clin Microbiol. 2006;44:2844-50.
• Raby E, Moyo M, Devendra A, Banda J, De Haas P, Ayles H, Godfrey-Faussett P. The effects of HIV on the sensitivity of a whole blood IFN-gamma release assay in Zambian adults with active tuberculosis. PLoS One. 2008;3:e2489.
• Balcells ME, Pérez CM, Chanqueo L, Lasso M, Villanueva M, Espinoza M, Villarroel L, García P. A comparative study of two different methods for the detection of latent tuberculosis in HIV-positive individuals in Chile. Int J Infect Dis. 2008;12:645-52.
• Jones S, de Gijsel D, Wallach FR, Gurtman AC, Shi Q, Sacks H. Utility of QuantiFERON-TB Gold in-tube testing for latent TB infection in HIV-infected individuals.Int J Tuberc Lung Dis. 2007;11:1190-5.
• Luetkemeyer AF, Charlebois ED, Flores LL, Bangsberg DR, Deeks SG, Martin JN, Havlir DV Comparison of an interferon-gamma release assay with tuberculin skin testing in HIV-infected individuals. Am J Respir Crit Care Med. 2007;175:737-42.
• Talati NJ, Seybold U, Humphrey B, Aina A, Tapia J, Weinfurter P, et al. Poor concordance between interferon-gamma release assays and tuberculin skin tests in diagnosis of latent tuberculosis infection among HIV-infected individuals. BMC Infect Dis. 2009;9:15.
• European Center for Disease Prevention and Control. Use of interferon-gamma release assays in support of http://ecdc.europa.eu/en/publications/Publications/11 03_GUI_IGRA.pdf Stockholm, 2011.
• Dorman SE, Belknap R, Graviss EA, Reves R, Schluger N, Weinfurter P, et al. Tuberculosis Epidemiologic Studies Consortium.Interferon-gamma release assays and tuberculin skin testing for diagnosis of latent tuberculosis infection in healthcare workers in the United States. Am J Respir Crit Care Med. 2014;189:77-87.
• Joshi M, Monson TP,Woods GL. Use of interferon- gamma release assays in a health care worker screening program: experience from a tertiary care centre in the United States. Can Respir J. 2012;19:84-8.
• Starke JR. The tuberculin skin test. Pediatric Annals 1993;22:6.
• Menzies R, Vissandgee B. Effect of Bacille Calmette-Guerin Vaccination on tuberculin reactivity. Am Rev Respir Dis. 1992;145:621-5.
• Sepulveda RL, Araya D, Ferrer X, Sorensen RU. Repeated tuberculin testing in patients with active pulmoner tuberculosis. Chest. 1993;103:359-63.
• Göksel T, Çok G, Çolakoğulları M, Bayındır Ü. Üniversite Öğrencilerinde Tüberkulin Müsbetliği. XXI. Ulusal Türk Tüberküloz ve Göğüs Hastalıkları Kongresi. Kongre Kitabı. 1996;359-62.
• Saraç S, Yurter G, Sancı N, Demiröz ÖF. Huzurevinde kalan yaşlılarda PPD sonuçlarının değerlendirilmesi. XXI. Ulusal Türk Tüberküloz ve Göğüs Hastalıkları Kongresi Kitabı. 1996;15-25.
• Abbas AK, Murphy KM, Sher A. Functional diversity of helper T lymphocytes. Nature. 1996;383:787–93.
• Mosmann TR, Sad S. The expanding universe of T- cell subsets: Th1, Th2 and more. Immunology Today. 1996;17:138–46,
• Wallis RS. Tumour necrosis factor antagonists: structure, function, and tuberculosis risks. Lancet Infect Dis. 2008;8:601-11.
• Scallon B, Cai A, Solowski N, Rosenberg A, Song XY, Shealy D, Wagner C. Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther. 2002;301:418- 26.
• Dinarello CA. Differences between anti-tumor necrosis factor monoclonal antibodies and soluble TNF receptors in host defense impairment. J Rheumatol suppl. 2005;74:40-7.
• Saliu OY, Sofer C, Stein DS, Schwander SK, Wallis RS.Tumor-necrosis-factor effects on mycobacterial immunity. J Infect Dis. 2006;194:486-92. blockers: differential
• Hanta I, Ozbek S, Kuleci S, Kocabas A. The evaluation of latent tuberculosis in rheumatologic diseases for anti-TNF therapy: experience with 192 patients. Clin Rheumatol. 2008;27:1083-6.
• Cagatay T, Aydin M, Sunmez S, Cagatay P, Gulbaran Z, Gul A, Artim B, Kilicaslan Z. Follow-up results of 702 patients receiving tumor necrosis factor-alpha antagonists and evaluation of risk of tuberculosis. Rheumatol Int. 2010;30:1459-63.
• Elbek O, Uyar M, Aydin N, Börekçi S, Bayram N, Bayram H, Dikensoy Oncreased risk of tuberculosis in patients treated with antitumor necrosis factor alpha. Clin Rheumatol. 2009;28:421-6.
• Doğan Ç, Kıral N, Cömert SŞ, Fidan A, Çağlayan B, Salepçi B. Anti TNF-alfa kullanan hastalarda tüberküloz sıklığı. Turk Toraks Derg. 2012;13:93-8.
• Jo KW, Hong Y, Jung YJ, Yoo B, Lee CK, Kim YG, Yang SK, et al.Incidence of tubeculosis among anti- tumor necrosis factor users in patients with a previous history of tuberculosis. Respir Med. 2013;107:1797-802.